Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Down 3.2% After Insider Selling

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price traded down 3.2% on Wednesday after an insider sold shares in the company. The company traded as low as $1,011.75 and last traded at $1,011.75. 102,833 shares changed hands during trading, a decline of 78% from the average session volume of 475,243 shares. The stock had previously closed at $1,044.66.

Specifically, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,208 shares of company stock valued at $62,514,142. 7.48% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,027.55.

Regeneron Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market cap of $111.91 billion, a price-to-earnings ratio of 30.52, a P/E/G ratio of 2.17 and a beta of 0.13. The stock’s 50-day moving average is $990.15 and its 200 day moving average is $954.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. Norges Bank acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $932,571,000. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares in the last quarter. Global Assets Advisory LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $339,594,000. Capital International Investors increased its holdings in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Finally, First Trust Advisors LP increased its holdings in Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after buying an additional 195,902 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.